Skip to main content

US-based Catalyst Clinical Research (CCR) has completed its first international acquisition, purchasing…

US-based Catalyst Clinical Research (CCR) made its first international acquisition by buying Aptus Clinical in the UK.

Bird & Bird partnered with Smith Anderson as legal advisors to CCR, while Aptus took legal advice from Squire Patton Boggs on the transaction which closed on April 29 and announced on May 4, and for which transaction values ​​have not been released.

CCR is owned by NovaQuest Private Equity, a US-based healthcare and life sciences investor, and provides clinical research solutions.

Founded in 2014 by three AstraZeneca alumni, Aptus is a CRO based in the North West of England conducting early phase clinical studies in oncology, rare diseases and cell and gene therapies .

The transaction creates a combined CRO operating in 35 countries with 800 employees.

In a statement, CCR CEO Nick Dyer said, “Our complementary service offerings and alignment with therapeutic areas will improve outcomes for all of our clients.

Bird & Bird brought in a team led by partners Simon Allport and Sally Shorthose, assisted by partner Elizabeth Lang, and a number of legal directors and partners on tax, real estate, data protection, intellectual property, financial and regulatory.

Smith Anderson’s team was led by managing partner Byron Kirkland, while Manchester partner and head of corporate practice Giles Chesher managed the contribution of Squire Patton Boggs.

Last month, Carlyle acquired British-American life sciences investment firm Abingworth.